Sulbutiamine

PreclinicalSmall molecule

SSohag University

Sulbutiamine is one of 12 small molecule programs targeting Enuresis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EnuresisActive, not recruiting

EnuresisPreclinical

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Enuresis

#DrugCompanyPhaseTrials

Indocin

CCosette Pharmaceuticals, Inc.

Approved

1 2

Pitressin

AAultman Health Foundation

Advil

Strattera

1 5

Tofranil

Sanofi

Preclinical

1 6

Depacon

AbbVie

Preclinical

1 7

Deltavit

HHyundai Pharmaceutical Co., LTD.

Propiverine

1 9

Sulbutiamine

SSohag University

Preclinical

1 10

Anticholinergic

SSeoul National University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Enuresis1 trial

New Treatment for Nocturnal Enuresis in Children

Recruiting·SSohag University·N/A·NCT06497647·450 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sulbutiamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sulbutiamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sulbutiamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sohag University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSohag University

Sulbutiamine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Enuresis1 trial

References

Drug Info

Quick Facts

Related News